Dermapharm Holding SE : From a one-off BioNTech anecdote to a sustainable and attractively priced growth story
>FY 2022 strongly benefited from BioNTech collaboration - When Dermapharm published its FY 2022 headline figures on 14 March, the benefits from the collaboration with BioNTech, were still a dominating factor. We estimate that some 30% of Dermapharm’s total FY 2022 EBITDA of € 360m was related to the contract with BioNTech (approx. € 110m est.). The impact on Dermapharm’s top line should have been some € 144m in our view. FY 2022 EBITDA met the lower end of the company...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.